Please find enclosed herewith newspaper publication for unaudited financial results under regulation 47 of the Securities Exchange Board of India ( Listing Obligation and Disclosure Requirements) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Boston Bio Systems Limited has informed BSE about newspaper advertisements published in Financial Express (English) and Financial Express (Gujarati) on 15 August 2025, containing its standalone unaudited financial results for the quarter ended 30 June 2025, which were approved by the Board on 14 August 2025. For Q1 FY26, the company reported total income from operations of Rs. 18.06 lakhs, slightly lower than Rs. 19.255 lakhs in the previous quarter (Q4 FY25) and Rs. 19.25 lakhs in the year-ago quarter. Net profit after tax stood at Rs. 4.0 lakhs, a notable turnaround from losses of Rs. 49.05 lakhs in Q4 FY25 and Rs. 54.73 lakhs in Q1 FY25. EPS came in at Rs. 0.06 versus losses of Rs. 0.70 and Rs. 0.78 in the comparative quarters. Equity share capital remained unchanged at Rs. 700.22 lakhs.
This is a routine regulatory filing (newspaper publication of already-approved results) and is not expected to move the stock price materially. However, the swing back to a small profit after consecutive quarterly losses may be viewed mildly positively by existing shareholders, though the absolute earnings size remains very small.